Insights+: Key Deals of JP Morgan Healthcare Conference 2021
Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy
Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy
Shots:
- Dewpoint to receive up front payment and up to $239M as research, development & commercial milestones along with royalties on sales of the therapies
- The companies collaborated for the development of therapies to treat DM1
- The companies will collaborate their expertise to advance the novel therapeutic solutions addressing the patients’ needs
Click here to read full press release/ article | Ref: PRNewswire | Image: Business Wire